PL348916A1 - Utilisation of 2-substituted 1,2-benzisothiazole derivatives and 3-substituted tetrahydropyridopyrimidinone derivatives for the prophylaxis and therapy of cerebral ischaemia - Google Patents

Utilisation of 2-substituted 1,2-benzisothiazole derivatives and 3-substituted tetrahydropyridopyrimidinone derivatives for the prophylaxis and therapy of cerebral ischaemia

Info

Publication number
PL348916A1
PL348916A1 PL99348916A PL34891699A PL348916A1 PL 348916 A1 PL348916 A1 PL 348916A1 PL 99348916 A PL99348916 A PL 99348916A PL 34891699 A PL34891699 A PL 34891699A PL 348916 A1 PL348916 A1 PL 348916A1
Authority
PL
Poland
Prior art keywords
substituted
derivatives
utilisation
prophylaxis
therapy
Prior art date
Application number
PL99348916A
Other languages
English (en)
Inventor
Gerd Steiner
Kurt Schellhaas
Wilfried Lubisch
Uta Holzenkamp
Dorothea Starck
Laszlo Szabo
Franz Emling
Francisco Javier Garcia-Ladona
Hans-Peter Hofmann
Liliane Unger
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of PL348916A1 publication Critical patent/PL348916A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
PL99348916A 1999-01-11 1999-12-22 Utilisation of 2-substituted 1,2-benzisothiazole derivatives and 3-substituted tetrahydropyridopyrimidinone derivatives for the prophylaxis and therapy of cerebral ischaemia PL348916A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19900544A DE19900544A1 (de) 1999-01-11 1999-01-11 Verwendung von Verbindungen der Formel I zur Prophylaxe und Therapie der zerebralen Ischämie
PCT/EP1999/010275 WO2000041697A1 (de) 1999-01-11 1999-12-22 Verwendung von 2-substituierten 1,2-benzisothiazol-derivaten und von 3-substituierten tetrahydropyridopyrimidinon-derivaten zur prophylaxe und therapie der zerebralen ischämie

Publications (1)

Publication Number Publication Date
PL348916A1 true PL348916A1 (en) 2002-06-17

Family

ID=7893835

Family Applications (1)

Application Number Title Priority Date Filing Date
PL99348916A PL348916A1 (en) 1999-01-11 1999-12-22 Utilisation of 2-substituted 1,2-benzisothiazole derivatives and 3-substituted tetrahydropyridopyrimidinone derivatives for the prophylaxis and therapy of cerebral ischaemia

Country Status (19)

Country Link
EP (1) EP1140099A1 (hu)
JP (1) JP2002534467A (hu)
KR (1) KR20010101440A (hu)
CN (1) CN1333685A (hu)
AR (1) AR029741A1 (hu)
AU (1) AU2285100A (hu)
BG (1) BG105688A (hu)
BR (1) BR9916888A (hu)
CA (1) CA2359390A1 (hu)
DE (1) DE19900544A1 (hu)
HU (1) HUP0200520A3 (hu)
IL (1) IL144145A0 (hu)
MX (1) MXPA01006966A (hu)
NO (1) NO20013408L (hu)
PL (1) PL348916A1 (hu)
SK (1) SK9682001A3 (hu)
TR (1) TR200102009T2 (hu)
WO (1) WO2000041697A1 (hu)
ZA (1) ZA200105473B (hu)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1560488B1 (en) 2002-11-05 2010-09-01 Glaxo Group Limited Antibacterial agents
JP4794446B2 (ja) * 2003-09-23 2011-10-19 メルク・シャープ・エンド・ドーム・コーポレイション イソキノリン系カリウムチャンネル阻害薬
US8097610B2 (en) * 2005-08-26 2012-01-17 Shionogi & Co., Ltd. Derivative having PPAR agonistic activity
WO2009038752A2 (en) * 2007-09-20 2009-03-26 Cortex Pharmaceuticals, Inc. 3-substituted 1,2,3-triazin-4-one's and 3-substituted 1,3-pyrimidinone's for enhancing glutamatergic synaptic responses
MA41168A (fr) 2014-12-17 2017-10-24 Acraf Nouveaux composés antibactériens
CN108484594B (zh) * 2018-02-09 2020-08-04 福建医科大学 一种烷氧基取代四氢吡啶并嘧啶类化合物或其可用盐及其制备方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3620643A1 (de) * 1985-06-22 1987-01-22 Sandoz Ag Thiazole, ihre herstellung und verwendung
DE3831888A1 (de) * 1988-09-20 1990-03-29 Troponwerke Gmbh & Co Kg Arzneimittel zur behandlung von apoplexia cerebri
JP3036789B2 (ja) * 1990-06-22 2000-04-24 三井化学株式会社 新規な複素環式化合物及び医薬組成物
DE19746612A1 (de) * 1997-10-22 1999-04-29 Basf Ag 2-Substituierte 1,2-Benzisothiazol-Derivate, ihre Herstellung und Verwendung
DE19747063A1 (de) * 1997-10-24 1999-04-29 Basf Ag 3-substituierte Tetrahydropyridopyrimidinon-Derivate, ihre Herstellung und Verwendung

Also Published As

Publication number Publication date
CA2359390A1 (en) 2000-07-20
BR9916888A (pt) 2001-11-20
HUP0200520A3 (en) 2003-04-28
SK9682001A3 (en) 2002-03-05
JP2002534467A (ja) 2002-10-15
KR20010101440A (ko) 2001-11-14
BG105688A (en) 2002-02-28
MXPA01006966A (es) 2002-04-10
AR029741A1 (es) 2003-07-16
WO2000041697A1 (de) 2000-07-20
CN1333685A (zh) 2002-01-30
HUP0200520A2 (hu) 2002-07-29
ZA200105473B (en) 2002-10-03
IL144145A0 (en) 2002-05-23
NO20013408D0 (no) 2001-07-10
EP1140099A1 (de) 2001-10-10
DE19900544A1 (de) 2000-07-13
TR200102009T2 (tr) 2002-01-21
NO20013408L (no) 2001-08-21
AU2285100A (en) 2000-08-01

Similar Documents

Publication Publication Date Title
HK1044537A1 (en) 1,4-benzothiazepine derivatives methods for the production thereof, medicaments containing these compounds and the use
IL143979A0 (en) Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
HK1051695A1 (en) N6 heterocyclic 8-modified andenosine derivatives.
HUP0203225A3 (en) Benzodiazepin derivatives, the production and use thereof
IL143349A0 (en) Azepinoindole derivatives, the production and use thereof
HK1047284A1 (en) 2-amino-benzoxazinone derivatives for the treatment of obesity
HUP0202477A3 (en) Use of phthalazine derivatives
IL139491A0 (en) Phthalazine derivatives as phosphodiesterase-4 inhibitors
ZA200107689B (en) 1-Arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of CNS disorders.
AU2001279709A1 (en) Pyrimidine derivatives and their use for preventing and treating cerebral ischaemia
AU4694999A (en) Use of thiazolidinedione derivatives for the treatment or prevention of cataracts
HUP0203611A3 (en) 14,15-beta-methylene substituted androgens and their use for preparation of the medicaments
GB2346147B (en) Stabilized metallocene polyolefins
PL343728A1 (en) Carbapenem derivatives, utilization thereof and intermediate compounds of the same
IL144145A0 (en) Utilisation of 2-substituted 1,2-benzisothiazole derivatives and 3-substituted tetrahydropyridopyrimidinone derivatives for the prophylaxis and therapy of cerebral ischaemia
AU1028501A (en) Isoquinoline and quinazoline derivatives for the treatment of cns disorders
HK1059782A1 (en) Indole derivatives useful for the treatment of cnsdisorders
HUP0001891A2 (en) Medicament for the treatment of migraine
SG82014A1 (en) The use of aryl-cyclohexylamine derivatives against cns disorders
HU9900123D0 (en) 1-isothiazolidinone derivatives of azetidine-2-one, processes for the preparation thereof and use thereof
AU2504101A (en) Device for carrying out the oscillation-induced selective treatment of malignantdiseases
GB9926985D0 (en) Use of substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphonamides and-cyanamides for the treatment of diseases
SI1068184T1 (en) N-aryloxyethylamine derivatives for the treatment of depression
AU4503801A (en) Temperature dependent neuronal rescue
SI1064273T1 (en) 1,3,4-thiadiazoles useful for the treatment of cmv infections

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)